Royalty Pharma Stock: Strong Execution, Expanding Pipeline And More Firepower Ahead (RPRX)
· seekingalpha.com
Royalty Pharma Q1 update: Portfolio & Royalty Receipts rose 10–13% to $925m/$887m, reinforcing 2030 target upside and buyback tailwinds. See more on RPRX here.
Royalty Pharma ( RPRX ) was one of our Strong Buy Recommendations in 2023 and has now delivered more than 100% in total return. The company released the Q1 prin...